

Lefamulin (XENLETA) CFU

## Lefamulin (XENLETA) Criteria for Use June 2020

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

*The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.*

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at [www.pbm.va.gov](http://www.pbm.va.gov) or <http://vawww.pbm.va.gov> for further information.

### Exclusion Criteria

**If the answer to ANY item below is met, then the patient should NOT receive lefamulin**

- Prolonged QT interval
- Patients with history of ventricular arrhythmias
- Pregnancy (pregnancy status should be verified in women of childbearing potential) or lactation\*
- Concomitant receipt of strong CYP3A4 inducers (e.g. rifampin, applies to both oral and injection) or strong CYP3A4 inhibitors (applies to oral only)
- Concomitant receipt of sensitive 3A4 substrates that prolong the QT interval (e.g. pimozide)
- Concomitant receipt of Class 1a or class III antiarrhythmic agents

### Inclusion Criteria

**The answers to ALL of the following must be fulfilled in order to meet criteria for lefamulin.**

- Prescriber is an VA/VA Community Care Infectious Diseases or other facility authorized provider
- Patient has a diagnosis of community acquired bacterial pneumonia
- PORT (PSI) classification of II, III or IV
- Women of childbearing age agree to a pregnancy test and to use appropriate contraception until at least 2 days after the last dose

### Additional Inclusion Criteria

**In addition, the answer to ONE of the following must be fulfilled in order to meet criteria:**

- Intolerance to fluoroquinolones, macrolides AND doxycycline
- Severe beta-lactam allergy AND high risk for FQ adverse events

*\*Lactating women may be considered for lefamulin if they discard milk during treatment and for 2 days after final dose*

---

Prepared: June 2020. Contact: Kelly Echevarria, PharmD, BCPS, AQ-ID, BCIDP, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services 10P4P

---

Updated version may be found at [PBM INTERnet](#) or [PBM INTRANet](#)